HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrea De Lerma Barbaro Selected Research

MHC class II transactivator protein

9/2010New strategies of mammary cancer vaccination.
8/2006Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.
6/2006CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrea De Lerma Barbaro Research Topics

Disease

9Neoplasms (Cancer)
10/2021 - 01/2003
3Adenocarcinoma
06/2009 - 06/2006
1T-Cell Leukemia (Leukemia, T Cell)
08/2006

Drug/Important Bio-Agent (IBA)

4Histocompatibility Antigens Class IIIBA
10/2010 - 06/2006
4VaccinesIBA
10/2010 - 06/2006
3MHC class II transactivator proteinIBA
09/2010 - 06/2006
2DNA (Deoxyribonucleic Acid)IBA
12/2007 - 01/2003
1Pharmaceutical PreparationsIBA
10/2015
1Interleukin-12 (IL 12)IBA
12/2007
1Melphalan (Alkeran)FDA LinkGeneric
12/2007
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2007
1Biological ProductsIBA
12/2007
1Fibronectins (Fibronectin)IBA
12/2007
1nuclear factor YIBA
08/2006
1Trans-Activators (Trans-Acting Factor)IBA
08/2006
1Neoplasm Antigens (Tumor Antigens)IBA
06/2006
1Transforming Growth Factor beta (TGF-beta)IBA
01/2003
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2003
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2003

Therapy/Procedure

5Immunotherapy
10/2021 - 12/2007
1Aftercare (After-Treatment)
12/2007
1Therapeutics
12/2007